Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Rapid initiation of cyclosporine and eltrombopag ahead of definitive treatment decreases autoimmunity and expedites marrow recovery in a prospective phase II trial

View Full Paper
Ask AI
Bookmark
Share

Authors

NLNicholas C.J. LeeJSJeanine SuperataBKByeong‐Teck Kang

Discussion

Loading...

Member takes

Overview

Phase II trial shows rapid initiation of cyclosporine and eltrombopag improves hematologic response in severe aplastic anemia, indicating potential changes to treatment protocols.

Key Points

  • Increased hemoglobin levels and overall hematologic response were observed after treatment initiation with cyclosporine and eltrombopag.
  • Less than 5% experienced treatment-related adverse events, highlighting the safety of this rapid intervention in severe aplastic anemia.
  • Patients had notable reductions in T-cell activation and pro-inflammatory cytokines, pointing to effective modulation of autoimmunity.
  • The study provides evidence for potentially revising treatment protocols for newly diagnosed severe aplastic anemia patients.

Cite This Study

Lee et al. (2025) studied this question.

synapsesocial.com/papers/69362f764fa91c937236e368https://doi.org/10.1182/blood-2025-979
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adding eltrombopag to immunosuppressive treatment with cyclosporine as front-line therapy for moderate aplastic anemia improves trilineage hematologic response: One-year analysis of the randomised, placebo-controlled, double-blind Phase III trial eltrombopag for moderate aplastic anemia (EMAA Trial)2025
  2. 2A novel reduced-toxicity conditioning regimen with busulfan/fludarabine/cyclophosphamide/anti-thymocyte globulin for severe aplastic anemia2025
  3. 3Long-term outcomes of intensive immunosuppressive therapy combined with eltrombopag in patients with severe aplastic anemia2025
  4. 4Rapid early remission in a patient with severe aplastic anemia: a case report of hetrombopag, cyclosporine, and danazol combination therapy2025
  5. 5Hetrombopag Added to Cyclosporine as the First‐Line Treatment for Patients With Non‐Severe Aplastic Anemia: A Phase 2 Multicenter Trial2026